Debra Stephanie Barker
Direktor/Vorstandsmitglied bei BERGENBIO ASA
Vermögen: 36 120 $ am 30.04.2024
Aktive Positionen von Debra Stephanie Barker
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BERGENBIO ASA | Direktor/Vorstandsmitglied | 13.03.2019 | - |
| DESTINY PHARMA PLC | Direktor/Vorstandsmitglied | 01.01.2020 | - |
| Independent Dir/Board Member | 01.01.2020 | - | |
| Vorstandsvorsitzender | 25.05.2023 | 01.09.2023 | |
| Technik-/Wissenschafts-/F&E-Leiter | 01.09.2023 | - | |
| CUREVAC N.V. | Direktor/Vorstandsmitglied | 22.06.2022 | - |
| ARIX BIOSCIENCE PLC | Direktor/Vorstandsmitglied | 10.08.2022 | - |
| Independent Dir/Board Member | 10.08.2022 | - | |
Hutman Diagnostics AG
 Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Direktor/Vorstandsmitglied | - | - |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Direktor/Vorstandsmitglied | - | - |
Arix Bioscience /Venture Capital/
 Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Direktor/Vorstandsmitglied | 01.08.2022 | - |
Karriereverlauf von Debra Stephanie Barker
Ehemalige bekannte Positionen von Debra Stephanie Barker
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| SPEXIS AG | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2017 | 31.12.2018 |
| NOVARTIS AG | Corporate Officer/Principal | - | - |
Ausbildung von Debra Stephanie Barker
| Queens' College Cambridge | Doctorate Degree |
| King's College London | Graduate Degree |
Statistik
International
| Vereinigtes Königreich | 6 |
| Schweiz | 4 |
| Deutschland | 3 |
Operativ
| Director/Board Member | 7 |
| Chief Tech/Sci/R&D Officer | 2 |
| Independent Dir/Board Member | 2 |
Sektoral
| Health Technology | 8 |
| Consumer Services | 3 |
| Finance | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 6 |
|---|---|
| SPEXIS AG | Health Technology |
| NOVARTIS AG | Health Technology |
| BERGENBIO ASA | Health Technology |
| DESTINY PHARMA PLC | Health Technology |
| CUREVAC N.V. | Health Technology |
| ARIX BIOSCIENCE PLC | Finance |
| Private Unternehmen | 3 |
|---|---|
Hutman Diagnostics AG
Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Health Technology |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Finance |
- Börse
- Insiders
- Debra Stephanie Barker
- Erfahrung
